Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
- PMID: 28287508
- PMCID: PMC5408594
- DOI: 10.3791/55027
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Abstract
Taxanes such as docetaxel belong to a group of microtubule-targeting agents (MTAs) that are commonly relied upon to treat cancer. However, taxane resistance in cancerous cells drastically reduces the effectiveness of the drugs' long-term usage. Accumulated evidence suggests that the mechanisms underlying taxane resistance include both general mechanisms, such as the development of multidrug resistance due to the overexpression of drug-efflux proteins, and taxane-specific mechanisms, such as those that involve microtubule dynamics. Because taxanes target cell microtubules, measuring microtubule dynamic instability is an important step in determining the mechanisms of taxane resistance and provides insight into how to overcome this resistance. In the experiment, an in vivo method was used to measure microtubule dynamic instability. GFP-tagged α-tubulin was expressed and incorporated into microtubules in MCF-7 cells, allowing for the recording of the microtubule dynamics by time lapse using a sensitive camera. The results showed that, as opposed to the non-resistant parental MCF-7CC cells, the microtubule dynamics of docetaxel-resistant MCF-7TXT cells are insensitive to docetaxel treatment, which causes the resistance to docetaxel-induced mitotic arrest and apoptosis. This paper will outline this in vivo method of measuring microtubule dynamic instability.
Similar articles
-
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017. PLoS One. 2017. PMID: 28787019 Free PMC article.
-
Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.BMC Cancer. 2014 Jan 22;14:37. doi: 10.1186/1471-2407-14-37. BMC Cancer. 2014. PMID: 24447372 Free PMC article.
-
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.Cancer Chemother Pharmacol. 2017 Jul;80(1):151-164. doi: 10.1007/s00280-017-3345-2. Epub 2017 May 31. Cancer Chemother Pharmacol. 2017. PMID: 28567478
-
Therapeutic strategies to overcome taxane resistance in cancer.Drug Resist Updat. 2021 Mar;55:100754. doi: 10.1016/j.drup.2021.100754. Epub 2021 Feb 27. Drug Resist Updat. 2021. PMID: 33691261 Review.
-
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.Cancer Treat Rev. 2012 Nov;38(7):890-903. doi: 10.1016/j.ctrv.2012.02.011. Epub 2012 Mar 31. Cancer Treat Rev. 2012. PMID: 22465195 Review.
Cited by
-
Dietary High-Fat Promotes Cognitive Impairment by Suppressing Mitophagy.Oxid Med Cell Longev. 2023 Jan 21;2023:4822767. doi: 10.1155/2023/4822767. eCollection 2023. Oxid Med Cell Longev. 2023. PMID: 36718278 Free PMC article.
-
Microtubule Integrity Is Associated with the Functional Activity of Mitochondria in HEK293.Cells. 2021 Dec 20;10(12):3600. doi: 10.3390/cells10123600. Cells. 2021. PMID: 34944107 Free PMC article.
References
-
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–2150. - PubMed
-
- Jassem J, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19(6):1707–1715. - PubMed
-
- Nabholtz JM, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(6):968–975. - PubMed
-
- Zelnak A. Overcoming taxane and anthracycline resistance. Breast J. 2010;16(3):309–312. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical